Becton, Dickinson and Company (NYSE:BDX - Get Free Report) was downgraded by The Goldman Sachs Group from a "buy" rating to a "neutral" rating in a research report issued to clients and investors on Friday,Briefing.com Automated Import reports. They presently have a $192.00 target price on the medical instruments supplier's stock. The Goldman Sachs Group's price target points to a potential upside of 13.24% from the company's previous close.
Other equities research analysts have also issued reports about the company. StockNews.com upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Wednesday, April 2nd. William Blair lowered Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a report on Thursday. Raymond James cut shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research note on Friday. Piper Sandler reduced their target price on shares of Becton, Dickinson and Company from $280.00 to $260.00 and set an "overweight" rating for the company in a research report on Wednesday, April 23rd. Finally, Barclays lowered their price target on shares of Becton, Dickinson and Company from $279.00 to $261.00 and set an "overweight" rating on the stock in a research report on Monday, April 7th. Six analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, Becton, Dickinson and Company has a consensus rating of "Hold" and an average target price of $242.88.
Read Our Latest Stock Analysis on BDX
Becton, Dickinson and Company Trading Down 18.1 %
Shares of NYSE:BDX opened at $169.56 on Friday. The business's 50 day moving average price is $215.99 and its 200-day moving average price is $226.21. Becton, Dickinson and Company has a 1 year low of $169.52 and a 1 year high of $251.99. The firm has a market capitalization of $48.69 billion, a price-to-earnings ratio of 28.17, a price-to-earnings-growth ratio of 1.63 and a beta of 0.35. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.28 by $0.07. The business had revenue of $5.27 billion for the quarter, compared to the consensus estimate of $5.35 billion. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. The company's revenue was up 4.5% compared to the same quarter last year. During the same period last year, the firm posted $3.17 earnings per share. On average, equities research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.
Becton, Dickinson and Company declared that its Board of Directors has authorized a stock repurchase program on Tuesday, January 28th that allows the company to repurchase 10,000,000 shares. This repurchase authorization allows the medical instruments supplier to repurchase shares of its stock through open market purchases. Stock repurchase programs are typically a sign that the company's board believes its stock is undervalued.
Insiders Place Their Bets
In related news, Director Jeffrey William Henderson bought 1,500 shares of the company's stock in a transaction that occurred on Monday, February 10th. The stock was purchased at an average price of $233.62 per share, for a total transaction of $350,430.00. Following the acquisition, the director now owns 8,015 shares of the company's stock, valued at approximately $1,872,464.30. This trade represents a 23.02 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Michael David Garrison sold 479 shares of the company's stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total value of $94,497.12. Following the transaction, the executive vice president now owns 4,887 shares in the company, valued at $964,107.36. This trade represents a 8.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 3,578 shares of company stock valued at $795,986 over the last quarter. 0.36% of the stock is owned by insiders.
Institutional Investors Weigh In On Becton, Dickinson and Company
Several institutional investors and hedge funds have recently modified their holdings of the company. Wesbanco Bank Inc. boosted its stake in shares of Becton, Dickinson and Company by 1.9% in the fourth quarter. Wesbanco Bank Inc. now owns 2,558 shares of the medical instruments supplier's stock valued at $580,000 after purchasing an additional 48 shares during the period. S.A. Mason LLC increased its position in shares of Becton, Dickinson and Company by 3.7% during the fourth quarter. S.A. Mason LLC now owns 1,414 shares of the medical instruments supplier's stock worth $321,000 after acquiring an additional 50 shares during the period. Hillsdale Investment Management Inc. boosted its holdings in Becton, Dickinson and Company by 1.7% in the fourth quarter. Hillsdale Investment Management Inc. now owns 3,060 shares of the medical instruments supplier's stock valued at $694,000 after purchasing an additional 50 shares during the period. Northcape Wealth Management LLC raised its position in Becton, Dickinson and Company by 0.5% in the 1st quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier's stock valued at $2,248,000 after purchasing an additional 51 shares in the last quarter. Finally, Americana Partners LLC increased its stake in shares of Becton, Dickinson and Company by 3.5% during the fourth quarter. Americana Partners LLC now owns 1,520 shares of the medical instruments supplier's stock worth $345,000 after buying an additional 52 shares during the period. Hedge funds and other institutional investors own 86.97% of the company's stock.
About Becton, Dickinson and Company
(
Get Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
